influenza
viru
envelop
viru
belong
orthomyxovirida
famili
caus
annual
epidem
infrequ
pandem
spanish
flu
pandem
well
asian
flu
hongkong
flu
pandem
caus
death
million
peopl
pandem
swine
origin
influenza
viru
well
outbreak
china
remind
world
threat
pandem
influenza
genom
influenza
viru
consist
eight
segment
neg
rna
strand
envelop
bilay
harbor
two
spike
glycoprotein
hemagglutinin
ha
neuraminidas
na
proton
channel
homotrimer
ha
abund
protein
viral
surfac
mediat
attach
host
cell
surfac
via
bind
sialic
acid
sa
residu
cellular
receptor
upon
endocyt
viru
uptak
trigger
fusion
envelop
endosom
membran
releas
viral
genom
cytoplasm
na
cleav
glycosid
bond
termin
sa
facilit
releas
bud
virion
cell
diagnost
antibodi
spike
protein
prefer
tool
identif
serotyp
virus
develop
therapeut
antibodi
influenza
challeng
high
viral
mutat
rate
antigen
drift
genet
reassort
viru
genom
antigen
shift
continu
lead
new
strain
escap
neutral
antibodi
goe
along
adapt
small
molecul
inhibitor
eg
oseltamivir
vaccin
temporarili
control
recur
epidem
influenza
antigen
chang
typic
ha
na
avian
bat
serotyp
influenza
viru
ha
known
three
adapt
human
antibodi
bind
region
hemagglutinin
conserv
among
serotyp
develop
demonstr
broad
specif
neutral
potenc
howev
develop
product
qualiti
control
antibodi
expens
time
consum
altern
short
peptid
bind
specif
spike
protein
produc
autom
highthroughput
synthesi
low
cost
habind
peptid
recent
obtain
phage
display
lead
structur
optim
natur
product
specif
toxin
bioinformat
tool
discoveri
side
effect
known
antiinflammatori
peptid
show
antivir
activ
epitopeori
access
bind
peptid
search
paratopederiv
peptid
variabl
region
specif
antibodi
antibodi
ha
describ
least
antigen
site
af
hatrim
identifi
local
either
receptor
bind
site
interfac
three
hamonom
site
like
stalk
sever
structur
complex
publish
deposit
protein
data
bank
pdb
inde
antibodi
describ
whose
ha
bind
mediat
mainli
one
cdr
name
inspir
find
chose
linear
peptid
correspond
cdr
vh
monoclon
antibodi
major
contact
domain
strain
antibodi
deriv
peptid
bind
ha
sa
bind
site
particular
belong
antigen
site
b
respect
bind
site
conserv
among
sever
ha
serotyp
provid
basi
peptid
broader
specif
use
complementari
experiment
theoret
approach
select
ha
bind
vhcdr
peptid
improv
potenti
inhibit
bind
final
infect
cell
influenza
viru
inhibitori
potenti
effici
cdrpeptid
improv
microarraybas
sitedirect
substitut
amino
acid
could
demonstr
broader
specif
select
peptid
bound
ha
human
avian
pathogen
influenza
strain
influenza
strain
aichi
reassort
low
pathogen
amut
rostock
harvest
allanto
fluid
hen
egg
viru
isol
clarifi
upon
low
speed
centrifug
x
g
min
concentr
ultracentrifug
x
g
h
safeti
reason
virus
prepar
spr
experi
inactiv
min
irradi
uvlight
ice
infect
inactiv
viru
preclud
use
mdck
ii
base
cellassay
remain
bind
abil
ha
proven
use
standard
hemagglutin
assay
ha
human
red
blood
cell
spr
measur
also
monoval
split
vaccin
influenza
strain
nih
access
new
york
nih
access
victoria
split
vaccin
pandemrix
glaxosmithklin
influenza
strain
nih
access
california
use
protein
concentr
determin
use
standard
bca
assay
thermo
fisher
scientif
addit
virus
titrat
ha
unit
viru
concentr
serial
dilut
twofold
pb
use
microtit
plate
human
red
blood
cell
german
red
cross
berlin
ab
ad
well
follow
incub
min
room
temperatur
last
well
show
hemagglutin
provid
ha
unit
per
viru
solut
rostock
strain
turkey
erythrocyt
use
addit
materi
use
ha
aichi
sino
biolog
infect
cytotox
assay
madindarbi
canin
kidney
epitheli
cell
mdck
ii
use
atcc
cell
cultiv
standard
cell
cultur
condit
dmem
supplement
fetal
calf
serum
fc
mm
lglutamin
humid
atmospher
hemagglutin
inhibit
assay
hai
perform
use
either
human
erythrocyt
sialosugar
aichi
turkey
erythrocyt
sialosugar
rostock
peptid
synthes
linker
immobil
without
linker
vitro
inhibit
assay
spr
base
bind
experi
antibodi
deriv
peptid
extend
ntermin
lysin
linker
kkkksgfllisnamid
peali
kkkkfydydvfyamid
pebli
pecli
spr
base
screen
viru
bind
singl
doubl
mutat
variant
pebli
use
lysin
variant
purchas
biosyntan
genecust
puriti
peptid
dissolv
water
dilut
appropri
buffer
immobil
spr
sensor
chip
spr
base
bind
inhibit
assay
perform
full
length
peptid
sgfllisngvhwvamid
pea
ardfydydvfyyamdamid
peb
doubl
mutant
ardfygydvffyamdamid
pebgf
biolog
assay
peb
pebgf
control
peptid
ardfydpdvfyyamdamid
pebp
appli
peptid
peptid
eb
phage
phage
mucroporin
synthes
rudolf
volkmer
berlin
hplc
purif
analysi
achiev
use
linear
solvent
gradient
tfa
water
b
tfa
acetonitril
gradient
b
min
uv
detector
nm
column
ident
peptid
valid
mass
spectrometri
use
malditof
microflex
lt
bruker
daltonik
esi
qtof
micro
micromass
lyophil
peptid
could
store
least
one
year
control
hplcm
analysi
stock
solut
peb
pebgf
pebp
prepar
initi
dissolv
dmso
follow
dilut
pb
mm
peptid
dmso
vv
solvat
improv
sonic
stock
solut
could
store
sever
week
circular
dichroism
cd
spectroscopi
determin
secondari
structur
melt
temperatur
perform
fig
use
jasco
cd
spectromet
cd
spectra
peptid
solut
record
nm
wavelength
step
primari
signal
millidegre
mdeg
record
molar
ellipt
deg
calcul
measur
perform
gehealthcar
bioscienc
ab
use
chip
run
buffer
hbsp
mm
hepe
mm
nacl
tween
ph
peptid
protein
immobil
via
amin
coupl
edcnh
flow
rate
accord
manufactur
instruct
ge
healthcar
optimum
preconcentr
evalu
use
acet
phosphat
buffer
mm
ph
ligand
concentr
immobil
biotinyl
sialyllactos
lectin
neutravidin
thermo
fisher
scientif
immobil
amin
coupl
ph
enabl
high
ligand
densiti
biotinyl
sialyllactos
inject
concentr
hbsp
min
sever
concentr
analyt
ha
viru
appli
least
onto
two
channel
gener
associ
dissoci
time
follow
regener
step
mm
naoh
flow
rate
use
quantit
data
obtain
extract
amount
bound
materi
inject
termin
mean
valu
revers
peptid
bind
experi
run
immobil
ha
aichi
condit
doubl
referenc
bind
curv
perform
use
control
flow
cell
without
ligand
use
control
inject
buffer
order
elimin
bulk
refract
index
effect
unspecif
bind
sensor
surfac
dissoci
constant
kd
calcul
plot
steadi
state
bind
level
analyt
concentr
use
biacor
evalu
softwar
constant
concentr
aichi
viru
use
analyt
concentr
inhibitor
vari
suspens
viru
inhibitor
mix
subsequ
incub
thermoshak
rpm
least
min
reach
equilibrium
inject
spr
surfac
inhibitor
use
peptid
sialyllactos
carbosynth
suspens
viru
inhibitor
mix
subsequ
incub
least
min
reach
equilibrium
inject
spr
surfac
data
referenc
buffer
inhibitor
inject
ident
concentr
decreas
bind
capac
chip
time
consid
referenc
multipl
viru
inject
variou
time
point
experi
inhibit
calcul
mean
valu
least
five
bind
event
viru
alon
use
sigmoid
four
paramet
logist
fit
origin
microarraybas
substitut
analysi
peptid
peb
perform
use
peptid
librari
spot
glass
slide
jpt
peptid
technolog
slide
use
without
addit
treatment
label
protein
fluoresc
dye
dyomic
nm
nm
fluorospin
kit
emp
biotech
use
accord
instruct
follow
materi
label
newyork
victoria
aichi
california
label
analyt
incub
sever
hour
overnight
indic
concentr
use
femtotip
buffer
ftp
mm
tri
glycerol
polyvinylpyrrolidon
tween
ph
dilut
slide
wash
twice
ftp
twice
ultrapur
water
subsequ
dri
stream
nitrogen
fluoresc
measur
perform
use
axon
laser
scanner
molecular
devic
fluoresc
intens
evalu
use
genepix
pro
softwar
evalu
bind
effici
contrast
c
calcul
cisincisinc
repres
rel
fluoresc
intens
background
subtract
sampl
spot
inc
rel
fluoresc
intens
appropri
neg
control
spot
mean
valu
triplic
experi
mutant
peptid
cm
given
rel
contrast
posit
control
fetuin
cm
x
percent
cpeb
set
zero
experiment
data
obtain
geo
access
id
assay
perform
accord
potier
et
al
recombin
neuraminidas
influenza
viru
purchas
antibodiesonlin
substrat
acid
sodium
salt
munana
obtain
carbosynth
assay
done
me
buffer
contain
mm
nmorpholino
ethan
sulfon
acid
mm
fluoresc
cleav
product
detect
fluostar
omega
micropl
reader
bmg
labtech
ortenberg
germani
excit
wavelength
nm
emiss
wavelength
nm
wellknown
inhibitor
neuramin
acid
disodium
salt
dana
carbosynth
use
posit
control
inhibit
assay
microtit
plate
well
fill
contain
ng
neuraminidas
substrat
variou
concentr
inhibitor
incub
min
assay
also
perform
aichi
uv
inactiv
ng
per
well
aichi
rostock
virus
incub
human
turkey
erythrocyt
respect
yield
agglutin
absenc
inhibitor
concentrationdepend
inhibit
agglutin
presenc
inhibitor
inhibitor
twofold
serial
dilut
pb
hemagglutin
unit
hau
contain
viru
particl
ad
well
viral
particl
concentr
estim
describ
desselberg
et
al
min
incub
room
temperatur
erythrocyt
solut
cell
ad
gentli
mix
incub
min
room
temperatur
aichi
human
erythrocyt
sialosugar
rostock
turkey
erythrocyt
sialosugar
use
inhibitor
constant
ki
hai
reflect
lowest
inhibitor
concentr
necessari
achiev
complet
inhibit
hemagglutin
caus
influenza
viru
check
full
hemagglutin
inhibit
microtit
plate
tilt
caus
droplet
format
red
blood
cell
pellet
experi
assess
use
mt
reagent
promega
accord
manufactur
protocol
mdck
ii
cell
seed
day
infect
aichi
rostock
pretreat
peptid
twofold
dilut
seri
min
room
temperatur
slight
agit
cell
wash
pb
supplement
mm
mm
pretreat
viru
moi
ad
cell
maintain
h
room
temperatur
allow
bind
unbound
viru
remov
wash
infect
medium
dmem
mm
lglutamin
fc
bovin
serum
albumin
bsa
l
ethyl
chloromethyl
keton
tpck
treat
trypsin
u
penicillin
streptomycin
subsequ
incub
h
mt
solut
ad
well
follow
hour
incub
final
absorb
nm
record
data
normal
follow
infect
inhibit
infectedtreatedinfecteduntr
uninfecteduntreatedinfecteduntr
experi
perform
viru
strain
least
triplic
experi
microneutr
assay
perform
accord
protocol
klimov
et
al
minor
modif
briefli
peptid
dilut
mix
either
aichi
rostock
infect
medium
min
room
temperatur
subsequ
mdck
ii
cell
ad
well
follow
incub
h
next
medium
remov
wash
pb
fix
ice
cold
aceton
vv
remov
fix
plate
dri
undergon
immunostain
cell
stain
igg
primari
antibodi
influenza
nucleoprotein
millipor
cat
mous
monoclon
antibodi
diluent
pb
tween
vv
wv
nonfat
dri
milk
h
room
temperatur
follow
cell
wash
wash
buffer
pb
tween
secondari
antibodi
goat
antimous
igg
kpl
cat
antibodi
diluent
conjug
horseradish
peroxidas
hrp
ad
anoth
hour
room
temperatur
next
antibodi
remov
cell
wash
wash
buffer
final
dihydrochlorid
opd
citrat
phosphatecitr
sodium
perbor
ph
ad
approxim
minut
supernat
turn
yellow
reaction
stop
sulfur
acid
absorb
reaction
product
microwel
plate
record
nm
subtract
background
noninfect
cell
neutral
calcul
ratio
untreat
infect
cell
one
day
treatment
mdck
ii
cell
seed
follow
day
media
remov
replac
twofold
serial
dilut
either
peb
pebgf
pebp
supplement
dmem
see
next
cell
incub
presenc
inhibitor
h
mt
solut
ad
well
final
absorb
nm
measur
data
normal
untreat
cell
follow
cell
viabil
treat
cellsmedium
background
untreat
cellsmedium
background
ensembl
configur
complex
hapea
hapeb
hapec
hapebgf
built
use
packag
program
origin
coordin
atom
taken
crystal
structur
pdbid
case
antibodi
moieti
except
sequenc
peptid
studi
eras
case
pebgf
silico
mutat
perform
system
solvat
use
water
molecul
model
extend
least
complex
nearli
water
molecul
ad
solvat
complex
result
truncat
octahedr
box
size
nearli
x
x
appropri
number
chlorid
ion
ad
keep
total
system
charg
neutral
bond
length
involv
hydrogen
atom
constrain
use
shake
algorithm
allow
usag
fs
timestep
temperatur
fix
k
use
langevin
thermostat
collis
frequenc
electrostat
interact
treat
use
particlemesh
ewald
pme
scheme
fourthord
bspline
interpol
toler
nonbond
cutoff
nonbond
pair
list
updat
everi
fs
simul
carri
accord
protocol
use
previou
studi
amber
forc
field
briefli
complex
configur
first
optim
step
steepest
descent
follow
anoth
step
conjug
gradient
minim
keep
atom
complex
restrain
initi
posit
weak
harmon
potenti
system
simul
ps
constant
volum
kcal
restraint
complex
order
equilibr
solvent
k
without
undesir
drift
structur
subsequ
ps
md
simul
kcal
restraint
complex
pressur
kpa
conduct
relax
densiti
use
berendsen
barostat
ns
without
restraint
equilibr
phase
ns
simul
constant
pressur
carri
coordin
store
everi
ps
result
configur
simul
subsequ
molecular
mechanicspoissonboltzmann
surfac
area
mmpbsa
calcul
perform
mmpbsa
method
bind
free
energi
receptorligand
complex
determin
gcom
grec
glig
denot
absolut
free
energi
complex
receptor
ligand
respect
method
discuss
elsewher
free
energi
g
speci
estim
gemmgsolvtmm
emm
molecular
mechan
energi
ga
phase
gsolv
solvat
free
energi
tsmm
contribut
conform
entropi
term
emm
compris
intern
bond
angl
dihedr
eint
electrostat
eelec
van
der
waal
energi
evdw
accord
emmeinteelecevdw
eintebondeangleetors
incorpor
possibl
nonbond
interact
term
emm
estim
snapshot
cutoff
solvat
free
energi
gsolv
approxim
sum
polar
gpol
nonpolar
contribut
gnp
use
continuum
represent
solvent
accord
gsolvgpolgnp
kcal
b
kcal
popular
linear
poissonboltzmann
method
use
estim
polar
compon
solvat
free
energi
sasa
solvent
access
surfac
area
estim
linear
combin
pairwis
overlap
lcpo
algorithm
use
probe
radiu
electrostat
contribut
solvat
free
energi
estim
poissonboltzmann
pb
approach
use
pbsa
solver
implement
amber
order
solv
pb
equat
grid
space
set
dimens
rel
dielectr
constant
protein
water
chosen
respect
ionic
strength
set
ratio
longest
dimens
rectangular
finitediffer
grid
solut
chosen
linear
pb
equat
solv
maximum
iter
order
understand
inhibitorresidu
interact
detail
interact
energi
decompos
contribut
residu
peptid
use
theori
free
energi
decomposit
peptideresidu
interact
approxim
contribut
van
der
waal
electrostat
interact
inhibitor
residu
ga
phase
polar
solvat
free
energi
estim
use
pbsa
modul
amber
structur
fabhemagglutinin
complex
antibodi
pdb
complex
immunoglobulin
ha
aichi
analyz
identifi
peptid
sequenc
fab
fragment
ha
contact
area
essenti
three
hypervari
complementar
determin
region
cdr
heavi
chain
variabl
domain
vh
fab
interact
ha
fig
three
looplik
organ
sequenc
interact
sa
bind
pocket
ha
peptid
pea
peb
pec
fig
deriv
contain
core
cdr
sequenc
tabl
order
predict
compar
bind
affin
ha
three
peptid
correspond
peptideha
complex
simul
explicit
water
model
ns
use
md
deduc
rootmeansquar
deviat
peb
alreadi
three
ns
steadi
state
bind
observ
fig
contrast
peptid
pea
dissoci
ha
within
simul
time
ns
gibb
free
energi
peptid
bind
ha
kcal
peb
pec
respect
tabl
even
though
absolut
valu
free
energi
chang
deriv
md
simul
proven
correl
exactli
experiment
valu
comparison
md
deriv
valu
implic
stronger
bind
peb
ha
also
shown
fig
peb
fit
best
conserv
sa
bind
site
aichi
ha
base
experiment
result
see
select
peb
potenti
inhibitor
viru
bind
host
cell
expect
short
primari
sequenc
reveal
experiment
cd
spectroscopi
peb
display
secondari
structur
element
solut
physiolog
ph
fig
unravel
molecular
basi
peb
bind
ha
analysi
energet
contribut
conduct
combin
mdmmpbsa
approach
molecular
configur
obtain
md
simul
complex
explicit
water
use
calcul
bind
free
energi
use
implicit
solvat
scheme
bind
free
energi
decompos
contribut
individu
peptid
residu
fig
peb
residu
within
close
loop
provid
largest
contribut
bind
free
energi
signific
attract
contribut
bind
free
energi
chang
aris
kcal
kcal
kcal
howev
contribut
repuls
kcal
kcal
respect
bind
free
energi
henc
exchang
amino
acid
would
predict
reduc
repuls
interact
residu
thu
increas
affin
modifi
peb
ha
detail
analysi
electrostat
van
der
waal
polar
contribut
free
energi
chang
residu
present
fig
also
analyz
contribut
individu
residu
ha
complex
attract
contribut
mainli
origin
residu
kcal
kcal
kcal
wherea
signific
repuls
contribut
caus
kcal
number
accord
pdb
fig
attract
contribut
polar
residu
aris
mainli
intermolecular
electrostat
interact
energi
wherea
hydrophob
residu
deriv
contribut
van
der
waal
interact
bind
aichi
viru
surfac
immobil
peptid
measur
use
spr
purpos
peptid
peali
pebli
pecli
contain
lysin
residu
amino
terminu
act
spacer
use
deduc
md
simul
nterminu
peb
significantli
contribut
bind
peptid
ha
contribut
residu
total
free
energi
chang
close
kcal
fig
peb
bind
respons
shown
fig
deduc
spr
sensorgram
bind
aichi
peptidecov
surfac
fig
signific
viru
bind
observ
peb
pec
peamodifi
surfac
consist
md
simul
minimum
detect
level
correspond
lowest
viru
concentr
show
bind
time
spr
respons
buffer
control
aichi
viru
protein
immobil
peb
pec
respect
higher
sensit
peb
viral
bind
assay
confirm
select
cdr
deriv
peptid
experi
mention
confirm
specif
three
peb
variant
contain
singl
amino
acid
residu
exchang
immobil
ligand
densiti
investig
bind
observ
three
variant
suggest
bind
viru
inde
specif
cdr
sequenc
fig
result
also
exclud
possibl
bind
mediat
oligolysin
terminu
furthermor
sever
wellknown
protein
test
unspecif
bind
peptid
modifi
chip
surfac
fig
protein
inject
mass
concentr
corestreptavidin
lysozym
minor
bind
peb
found
show
surfac
inert
impair
like
virus
bind
peptidecov
surfac
multival
manner
see
discuss
possibl
calcul
reliabl
bind
constant
multival
bind
invers
experi
use
surfac
immobil
ha
aichi
perform
steadyst
affin
calcul
peb
bind
constant
kd
rmax
ru
obtain
fig
assess
whether
peb
bind
thu
block
sialic
bind
pocket
aichi
neuraminidas
enzym
activ
assay
substrat
munana
perform
detail
see
materi
method
neuraminidas
inhibitor
dana
acid
serv
posit
control
abl
inhibit
neuraminidas
activ
peb
reduc
catalyt
activ
enzym
peptid
concentr
fig
thu
peb
compromis
access
catalyt
cleft
na
support
specif
bind
inhibit
bind
aichi
surfac
immobil
fetuin
peb
studi
fetuin
contain
sialic
acid
ha
bind
constitu
surfac
epitheli
cell
shown
fig
aichi
bind
fetuin
inhibit
peb
sigmoid
fit
valu
peb
calcul
furthermor
peb
also
prevent
bind
aichi
sialyllactos
immobil
spr
chip
lower
concentr
solubl
sialyllactos
valu
respect
fig
result
provid
evid
peb
compet
success
sa
bind
site
thu
may
serv
viru
bind
inhibitor
md
simul
shown
main
contribut
peb
bind
ha
origin
residu
peptid
search
peptid
higher
bind
affin
full
substitut
analysi
use
microarray
perform
thu
peb
mutant
variant
gener
fulllength
sequenc
preserv
except
one
amino
acid
eight
loopform
amino
acid
origin
peb
peptid
ardfydydvfyyamd
substitut
remain
natur
amino
acid
fig
assess
bind
aichi
label
protein
react
fluorophor
notabl
substitut
gener
lead
increas
bind
signal
agreement
md
simul
predict
residu
caus
repuls
forc
kcal
interact
ha
furthermor
substitut
g
predict
provid
high
attract
contribut
kcal
reduc
obtain
fluoresc
signal
although
result
essenti
consist
theoret
predict
notic
deviat
follow
microarray
result
aspart
acid
seem
essenti
bind
md
simul
assign
repuls
notabl
substitut
observ
also
enhanc
bind
viru
microarray
approach
appli
influenza
viru
strain
higher
medic
relev
fig
new
york
victoria
california
similar
aichi
substitut
increas
bind
california
rather
new
york
howev
latter
well
victoria
substitut
residu
caus
significantli
enhanc
bind
strain
substitut
lead
enhanc
affin
viru
bind
select
peptid
variant
evalu
spr
identifi
variant
improv
bind
particularli
interest
variant
show
bind
variou
influenza
viru
strain
end
sever
doubli
substitut
variant
probe
base
result
monosubstitut
variant
see
chosen
substitut
fig
show
result
bind
three
viru
strain
pebli
mono
doublesubstitut
variant
best
variant
pebgf
sequenc
ardfygydvffyamd
repuls
amino
acid
kcal
slightli
attract
residu
kcal
see
md
simul
replac
g
f
respect
contribut
total
bind
free
energi
chang
everi
amino
acid
pebgf
bind
ha
aichi
obtain
mdsimul
shown
fig
mutat
decreas
contribut
free
energi
chang
residu
fig
discuss
alter
moder
interact
ha
induc
favor
contribut
chang
interact
neighbor
residu
phenylalanin
ha
side
chain
residu
orient
toward
solvent
peb
due
polar
properti
hand
absenc
oh
group
residu
side
chain
pebgf
induc
slight
chang
orient
loop
tilt
phenylalanin
side
chain
toward
hydrophob
region
ha
locat
residu
amount
hemagglutinin
bound
pebgf
compar
peb
aichi
new
york
california
respect
specif
bind
pebgf
receptor
bind
site
ha
evidenc
spr
fig
tabl
compar
peb
pebgf
show
lower
vs
inhibit
aichi
bind
fetuinimmobil
spr
surfac
peb
observ
minor
tendenc
bind
immobil
fetuin
becom
obviou
calcul
inhibit
valu
higher
character
potenti
antibodi
deriv
peptid
prevent
viru
replic
studi
viru
bind
infect
host
cell
presenc
peb
pebgf
pebp
latter
assum
structur
distinct
variant
due
presenc
prolin
residu
use
neg
control
peb
pebgf
effici
prevent
aichi
mediat
aggreg
red
blood
cell
rbc
assess
hai
fig
howev
pebgf
much
effici
comparison
peb
inhibitori
constant
ki
hai
peb
pebgf
respect
furthermor
could
show
bind
inhibit
rostock
viru
turkey
erythrocyt
ki
hai
valu
peb
pebgf
tabl
hemagglutin
viral
strain
inhibit
pebp
peptid
also
protect
effici
mdck
ii
cell
infect
moi
aichi
fig
rostock
fig
pebp
compromis
infect
importantli
three
peptid
impair
cell
viabil
within
h
treatment
peptid
maximum
concentr
studi
fig
similar
result
obtain
microneutr
assay
peptid
inhibitor
present
solut
throughout
whole
h
incub
fig
tabl
viral
nucleoprotein
express
detect
immunostain
infect
cell
result
compar
untreat
infect
cell
valu
rostock
similar
obtain
mt
base
infect
inhibit
assay
howev
valu
aichi
somewhat
lower
fold
respect
mt
assay
although
micromolar
valu
seem
rather
high
concentr
point
view
medic
applic
result
promis
develop
multival
inhibitor
see
discuss
evalu
inhibitori
potenti
antibodi
deriv
peptid
relat
alreadi
publish
ha
bind
peptid
compar
peptid
hai
assay
fig
normal
ki
hai
valu
natur
receptor
reduct
ki
hai
fold
peb
respect
pebgf
show
superior
potenti
compar
publish
peptid
except
entri
blocker
eb
previou
experi
peptid
pebgf
show
higher
inhibitori
potenc
peb
observ
lower
ki
hai
addit
peptid
show
lower
ki
hai
valu
peptid
obtain
phage
display
entri
blocker
eb
show
superior
hemagglutin
inhibit
reveal
lower
ki
hai
compar
pebgf
howev
due
amphiphil
charact
eb
form
micel
thu
may
act
multival
manner
therefor
inhibit
aichi
hemagglutin
effici
monoval
peptid
sake
complet
mention
mucroporin
show
strong
hemolyt
effect
strong
interfer
gold
surfac
made
imposs
obtain
reliabl
data
aim
obtain
peptid
inhibitor
recogn
conserv
region
sialic
acid
bind
pocket
ha
broader
specif
cover
sever
influenza
viru
strain
three
cdr
vhchain
antibodi
hemagglutinin
influenza
viru
aichi
use
templat
design
peptid
potenti
inhibitor
viru
bind
host
cell
use
complementari
experiment
approach
spr
peptid
microarray
md
select
appropri
peptid
enhanc
affin
ha
site
direct
substitut
amino
acid
valid
assess
potenti
prevent
viru
bind
cell
surfac
eventu
infect
host
cell
three
peb
deriv
three
cdr
sequenc
antibodi
heavi
chain
agreement
predict
md
calcul
peptideha
complex
found
spr
experi
bind
surfac
immobil
peptid
peb
ha
aichi
superior
pec
fig
therefor
peb
match
conserv
sialic
acid
bind
site
better
pec
pdb
subsequ
studi
perform
peb
deriv
inhibit
viru
bind
surfac
immobil
fetuin
sialyllactos
peb
confirm
specif
bind
peptid
sialic
acid
bind
pocket
ha
valu
rang
depend
assay
one
order
magnitud
lower
import
observ
may
also
interest
upcom
studi
found
specif
bind
virus
surfac
immobil
peptid
consist
amino
acid
repres
peb
core
sequenc
four
lysin
long
linker
fig
nevertheless
peb
deriv
harbor
amino
acid
essenti
recognit
sa
presum
effici
binder
monomer
form
affin
peptid
micromolar
rang
wherea
report
kd
valu
antibodi
bind
hemagglutinin
aichi
nm
howev
weak
bind
interact
shorter
monomer
peptid
could
enhanc
multival
interact
occur
like
spr
base
experi
bind
even
virus
immobil
peb
could
detect
fig
extens
c
ntermini
cdr
sequenc
could
import
format
stabl
peptid
structur
expos
cdr
loop
region
nativ
arrang
ii
direct
involv
bind
foster
interact
ha
accord
md
simul
peb
adopt
strandloopstrand
conform
loop
consist
residu
shown
fig
residu
within
adjac
loop
includ
residu
yield
largest
contribut
bind
free
energi
contribut
attract
neg
free
energi
chang
also
repuls
posit
free
energi
chang
contribut
amino
acid
free
energi
calcul
mmpbsa
larg
consist
result
microarraybas
substitut
analysi
despit
describ
discrep
possibl
substitut
chang
secondari
structur
lead
lower
affin
light
improv
affin
peb
enabl
broader
specif
also
probe
bind
peptid
ha
viru
strain
microarraybas
substitut
analysi
identifi
also
import
residu
improv
bind
base
investig
affin
select
variant
peb
two
substitut
screen
identifi
pebgf
best
binder
two
substitut
alter
ligand
moieti
bind
contact
result
favor
chang
contribut
free
energi
chang
residu
fig
mutat
residu
replac
charg
amino
acid
neutral
one
result
two
major
chang
firstli
induc
decreas
electrostat
contribut
bind
free
energi
chang
larg
overcom
increas
contribut
polar
solvat
free
energi
chang
fig
hand
one
notic
residu
locat
close
contact
loop
region
consequ
peb
involv
repuls
interact
two
neg
charg
residu
replac
uncharg
residu
pebgf
probabl
induc
slight
reorgan
loop
structur
favor
van
der
waal
polar
solvat
interact
contribut
residu
ha
moieti
fig
due
orient
toward
sa
bind
region
ha
sequenc
antibodi
ha
aichi
promis
candid
get
variant
broad
influenza
strain
specif
inde
peptid
peb
pebgf
found
bind
ha
strain
rostock
new
york
california
worth
note
differ
influenza
subtyp
could
bound
inhibit
peptid
peb
pebgf
reveal
strong
structur
similar
especi
amino
acid
involv
peptid
bind
tabl
close
relat
support
wide
bind
abil
inhibitori
potenc
peb
varieti
influenza
strain
broader
specif
also
support
similar
mous
antibodi
aichi
hemagglutinin
pdb
antibodi
amino
acid
aafyydydfffdi
pdb
antibodi
amino
acid
rdfydydvfyyam
also
human
antibodi
egdydiltgyyyyfdi
respect
notabl
enrich
aromat
amino
acid
tyr
phe
asp
line
find
recent
publish
human
antibodi
show
higher
proport
aromat
amino
acid
domain
crucial
role
asp
residu
hydrophob
amino
acid
ha
bind
mani
receptor
mimick
antibodi
highlight
lee
et
al
shown
exemplarili
aichi
rostock
inhibit
viru
bind
peptid
lead
strong
protect
viru
infect
host
cell
mt
base
infect
inhibit
assay
pebgf
found
superior
respect
peb
similar
observ
made
rostock
use
microneutr
assay
provid
direct
measur
viral
replic
howev
aichi
find
prefer
pebgf
indic
strain
depend
differ
antivir
potenti
peptid
inhibitori
potenti
antibodi
deriv
peptid
demonstr
remark
perform
compar
publish
peptid
bind
ha
fig
summar
tabl
peb
pebgf
provid
better
inhibit
aichi
compar
rostock
except
result
hai
assay
howev
take
consider
perform
peptid
inhibitor
depend
mani
factor
consequ
hemagglutin
inhibit
effici
may
necessarili
stronger
aichi
even
though
peptid
deriv
antibodi
bind
influenza
strain
one
specul
rostock
prone
neutral
block
bind
site
aichi
peb
pebgf
displac
easili
bind
competit
experi
erythrocyt
trend
could
also
explain
use
erythrocyt
deriv
differ
speci
see
materi
method
similar
straindepend
effici
obtain
et
al
although
peptid
design
broadli
conserv
epitop
antivir
effici
test
serotyp
three
differ
strain
short
oligomer
biomolecul
suffici
affin
high
interest
diagnost
drug
design
develop
synthesi
chemic
modif
easi
implement
linear
short
cdr
deriv
peptid
use
expect
differ
loop
structur
adopt
within
antibodi
lead
lower
affin
howev
promis
way
larg
improv
cyclis
cdr
peptid
use
dprolpro
templat
shown
forc
canon
conform
report
loop
antibodi
adopt
hairpin
structur
aromat
tstack
antibodi
crystal
structur
strategi
gener
peptidomimet
stabil
mimick
turn
helic
recent
review
wherea
gain
affin
cycliz
peptid
limit
affin
nativ
structur
larger
improv
achiev
multival
especi
viru
high
target
protein
densiti
surfac
bound
exampl
sialylcontain
oligosaccharid
constitut
natur
receptor
hemagglutinin
mammalian
epitheli
cell
exhibit
millimolar
affin
due
multival
viruscel
attach
bind
strong
enough
enabl
infect
effect
inhibit
influenza
viru
infect
multival
sialicacidfunction
gold
nanoparticl
glycoarchitectur
describ
recent
trival
glycopeptid
mimet
contain
three
sialyl
residu
match
three
sialyl
bind
site
ha
trimer
report
bind
hemagglutinin
fold
better
monom
recent
demonstr
antivir
effect
acyl
pebgf
increas
upon
present
multival
fashion
rostock
aichi
multival
present
short
peptid
arlpr
dendrim
result
submicromolar
inhibitori
activ
antibodi
deriv
peptid
peb
mutant
variant
pebgf
promis
hemagglutinin
bind
peptid
could
potenti
applic
viral
diagnost
therapeut
infect
inhibit
could
achiev
micromolar
concentr
strategi
improv
peptid
structur
appli
peptid
develop
multival
binder
high
affin
discuss
final
workflow
present
involv
complementari
experiment
theoret
approach
could
templat
develop
antivir
agent
could
also
appli
influenza
detect
biochip
coevolutionari
approach
peptid
primari
sequenc
may
also
adapt
season
upcom
mutat
influenza
viru
minor
addit
effort
cost
short
time
without
addit
develop
novel
monoclon
antibodi
